Neuralink has taken an important step in advancing its innovative brain-computer interface (BCI) technology by launching its first international clinical trial in Canada. The trial Called the CAN-PRIME Study has received approval from Health Canada followed by the success of Neuralink's PRIME Study in the United States. It aims to test the safety and basic functionality of Neuralink's fully implantable, wireless brain chip, designed to assist individuals with neurological conditions such as quadriplegia.
The CAN-PRIME Study is inviting six Canadian residents who have limited or no hand mobility due to conditions like amyotrophic lateral sclerosis (ALS) or cervical spinal cord injuries. The trial will evaluate Neuralink's N1 Implant and R1 Robot, which precisely inserts fine threads into the brain. This system allows users to control external devices such as computers or smartphones using their thoughts. The study will gather essential data on the safety of the device and its ability to improve the quality of life for individuals with severe mobility issues.
Initial results from the ongoing US trials have been encouraging. Participants have successfully used the implant to engage in activities like playing video games, browsing online and creating 3D designs. Neuralink's decision to expand its research to Canada reflects its global vision to make advanced BCI technology accessible, offering new possibilities for greater independence and mobility to individuals living with paralysis.
